- Home
- GSBC vs SNY Comparison
GSBC vs SNY Comparison
Compare GSBC & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- SNY
- Stock Information
- Founded
- GSBC 1923
- SNY 1994
- Country
- GSBC United States
- SNY France
- Employees
- GSBC N/A
- SNY N/A
- Industry
- GSBC Major Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- GSBC Finance
- SNY Health Care
- Exchange
- GSBC Nasdaq
- SNY Nasdaq
- Market Cap
- GSBC 665.7M
- SNY 116.5B
- IPO Year
- GSBC N/A
- SNY N/A
- Fundamental
- Price
- GSBC $58.99
- SNY $48.12
- Analyst Decision
- GSBC Hold
- SNY Buy
- Analyst Count
- GSBC 2
- SNY 2
- Target Price
- GSBC $59.50
- SNY $62.50
- AVG Volume (30 Days)
- GSBC 68.7K
- SNY 2.1M
- Earning Date
- GSBC 07-16-2025
- SNY 07-24-2025
- Dividend Yield
- GSBC 2.70%
- SNY 3.31%
- EPS Growth
- GSBC 10.52
- SNY 39.56
- EPS
- GSBC 5.60
- SNY 5.45
- Revenue
- GSBC $219,572,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- GSBC N/A
- SNY $3.39
- Revenue Next Year
- GSBC $1.04
- SNY $7.05
- P/E Ratio
- GSBC $10.59
- SNY $8.86
- Revenue Growth
- GSBC N/A
- SNY N/A
- 52 Week Low
- GSBC $47.58
- SNY $45.80
- 52 Week High
- GSBC $68.02
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- GSBC 64.15
- SNY 41.60
- Support Level
- GSBC $54.98
- SNY $47.56
- Resistance Level
- GSBC $59.49
- SNY $48.93
- Average True Range (ATR)
- GSBC 1.29
- SNY 0.64
- MACD
- GSBC 0.26
- SNY -0.06
- Stochastic Oscillator
- GSBC 96.90
- SNY 26.24
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.